Results of ECP in Patients With Chronic GVHD
| Patient No. . | Acute GVHD . | Chronic GVHD . | Therapy Before ECP . | BMT-ECP (mo) . | No. of ECP Cycles . | Duration of ECP (mo) . | Response to ECP . | Current Therapy . | Time Off ECP (mo) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade . | Onset (d) . | Type . | Histo . | Onset (d) . | Skin . | Joints . | Mouth . | Liver . | Ocular . | Thrombopenia . | |||||||
| 1 | III | 10 | P | S | 110 | CSA | 6 | 21 | 15 | CR | PR | CR | CR | NA | CR | A | 25 |
| 2 | II | 14 | P | S | 100 | CSA, MP | 17 | 17 | 14 | CR | NA | CR | NA | NA | NA | NONE | 9 |
| 3 | I | 19 | P | L + S | 110 | CSA, MP | 17 | 19 | 11 | PR | NA | CR | CR | NA | NA | NONE | NA |
| 4 | II | 11 | P | L | 63 | CSA, MP | 3 | 16 | 10 | CR | NA | NA | NA | NA | NA | NONE | 27 |
| 5 | II | 15 | Q | S | 229 | CSA, MP | 13 | 17 | 10 | CR | PR | CR | NA | CR | NA | A | 16 |
| 6 | I | 19 | P | L + S | 154 | MP | 8 | 16 | 8 | CR | NA | CR | CR | PR | NA | NONE | 1 |
| 7 | II | 16 | Q | S | 397 | CSA, MP, T | 23 | 23 | 22 | CR | PR | CR | CR | NA | NA | CSA | 13 |
| 8 | II | 23 | Q | S | 161 | MP, A | 11 | 27 | 18 | PR | PR | CR | PR | PR | NA | NONE | NA* |
| 9 | II | 20 | P | S | 74 | CSA, MP | 3 | 16 | NA | CR | NA | CR | CR | PR | NA | MP, A | NA* |
| 10 | I | 16 | P | L + S | 100 | CSA, MP, T, PUVA | 14 | 11 | 6 | CR | NA | CR | PR | PR | NC | NONE | NA* |
| 11 | II | 20 | P | L + S | 83 | CSA, MP | 5 | 47 | 31 | PR | NA | CR | NC | NC | CR | CSA | NA* |
| 12 | II | 20 | Q | L + S | 120 | CSA | 4 | 8 | 4 | CR | NA | NA | CR | NA | NA | NONE | 22 |
| 13 | 0 | NA | N | S | 730 | MP, PUVA | 44 | 7 | 6 | CR | NA | NA | NA | NA | NA | NONE | 16 |
| 14 | III | 11 | Q | L | 140 | MP | 11 | 8 | 5 | CR | NA | CR | CR | NA | NA | NONE | 21 |
| 15 | II | 22 | Q | L | 104 | CSA, MP | 4 | 12 | 11 | CR | NA | NA | NA | NA | NA | NONE | 24 |
| Patient No. . | Acute GVHD . | Chronic GVHD . | Therapy Before ECP . | BMT-ECP (mo) . | No. of ECP Cycles . | Duration of ECP (mo) . | Response to ECP . | Current Therapy . | Time Off ECP (mo) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade . | Onset (d) . | Type . | Histo . | Onset (d) . | Skin . | Joints . | Mouth . | Liver . | Ocular . | Thrombopenia . | |||||||
| 1 | III | 10 | P | S | 110 | CSA | 6 | 21 | 15 | CR | PR | CR | CR | NA | CR | A | 25 |
| 2 | II | 14 | P | S | 100 | CSA, MP | 17 | 17 | 14 | CR | NA | CR | NA | NA | NA | NONE | 9 |
| 3 | I | 19 | P | L + S | 110 | CSA, MP | 17 | 19 | 11 | PR | NA | CR | CR | NA | NA | NONE | NA |
| 4 | II | 11 | P | L | 63 | CSA, MP | 3 | 16 | 10 | CR | NA | NA | NA | NA | NA | NONE | 27 |
| 5 | II | 15 | Q | S | 229 | CSA, MP | 13 | 17 | 10 | CR | PR | CR | NA | CR | NA | A | 16 |
| 6 | I | 19 | P | L + S | 154 | MP | 8 | 16 | 8 | CR | NA | CR | CR | PR | NA | NONE | 1 |
| 7 | II | 16 | Q | S | 397 | CSA, MP, T | 23 | 23 | 22 | CR | PR | CR | CR | NA | NA | CSA | 13 |
| 8 | II | 23 | Q | S | 161 | MP, A | 11 | 27 | 18 | PR | PR | CR | PR | PR | NA | NONE | NA* |
| 9 | II | 20 | P | S | 74 | CSA, MP | 3 | 16 | NA | CR | NA | CR | CR | PR | NA | MP, A | NA* |
| 10 | I | 16 | P | L + S | 100 | CSA, MP, T, PUVA | 14 | 11 | 6 | CR | NA | CR | PR | PR | NC | NONE | NA* |
| 11 | II | 20 | P | L + S | 83 | CSA, MP | 5 | 47 | 31 | PR | NA | CR | NC | NC | CR | CSA | NA* |
| 12 | II | 20 | Q | L + S | 120 | CSA | 4 | 8 | 4 | CR | NA | NA | CR | NA | NA | NONE | 22 |
| 13 | 0 | NA | N | S | 730 | MP, PUVA | 44 | 7 | 6 | CR | NA | NA | NA | NA | NA | NONE | 16 |
| 14 | III | 11 | Q | L | 140 | MP | 11 | 8 | 5 | CR | NA | CR | CR | NA | NA | NONE | 21 |
| 15 | II | 22 | Q | L | 104 | CSA, MP | 4 | 12 | 11 | CR | NA | NA | NA | NA | NA | NONE | 24 |
Abbreviations: P, progressive; Q, quiescent; N, de novo; S, sclerodermoid; L, lichen planus-like; L + S, lichenoid and sclerodermatous; T, thalidomide; A, azathioprine; NC, no change; NA*, still under ECP.